These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 34426943)

  • 1. How to Sequence Therapies in Waldenström Macroglobulinemia.
    Sarosiek S; Treon SP; Castillo JJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.
    Treon SP; Sarosiek S; Castillo JJ
    Blood; 2024 Apr; 143(17):1702-1712. PubMed ID: 38211337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
    Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
    Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How I treat Waldenström macroglobulinemia.
    Treon SP
    Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
    Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
    Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
    [No Abstract]   [Full Text] [Related]  

  • 9. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
    Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
    Tawfiq RK; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Waldenström macroglobulinemia in 2020.
    Castillo JJ; Treon SP
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
    Castillo JJ; Buske C; Trotman J; Sarosiek S; Treon SP
    Am J Hematol; 2023 Feb; 98(2):338-347. PubMed ID: 36415104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
    Treon SP; Xu L; Guerrera ML; Jimenez C; Hunter ZR; Liu X; Demos M; Gustine J; Chan G; Munshi M; Tsakmaklis N; Chen JG; Kofides A; Sklavenitis-Pistofidis R; Bustoros M; Keezer A; Meid K; Patterson CJ; Sacco A; Roccaro A; Branagan AR; Yang G; Ghobrial IM; Castillo JJ
    J Clin Oncol; 2020 Apr; 38(11):1198-1208. PubMed ID: 32083995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future therapeutic options for patients with Waldenström macroglobulinemia.
    Castillo JJ; Hunter ZR; Yang G; Argyropoulos K; Palomba ML; Treon SP
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):206-215. PubMed ID: 27825467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
    Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
    Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Waldenström macroglobulinemia.
    Baďurová K; Gregorová J; Vlachová M; Krejčí M; Ševčíková S
    Klin Onkol; 2021; 34(6):428-433. PubMed ID: 34911327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is new in the treatment of Waldenstrom macroglobulinemia?
    Castillo JJ; Treon SP
    Leukemia; 2019 Nov; 33(11):2555-2562. PubMed ID: 31591468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.
    Zanwar S; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2020 Feb; 15(1):31-43. PubMed ID: 32006301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for the treatment of Waldenström macroglobulinemia.
    Despina F; Meletios Athanasios D; Efstathios K
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):433-444. PubMed ID: 32955949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
    Argyropoulos KV; Palomba ML
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.